Article Figures & Data
Figures
- FIGURE 1.
Biodistribution in typical female participant at 52 ± 6 min after administration of [18F]FDHT. Figure shows PET/CT images of participant with breast cancer imaged at S0, S1, and S2. At top are maximum-intensity projection images, and at bottom are coronal PET/CT images at level of gallbladder and bile duct.
- FIGURE 2.
[18F]FDHT SUVorgan measurements in liver of women with breast cancer at S0, S1, and S2. (Left) Spaghetti plot showing changes in measurements in individuals across all time points. (Right) Box plot showing median, interquartile range, and mean (+) of measurements over the 11 participants at each time point. Linear mixed model analysis found statistically significant decrease in uptake in individual participants at S1 compared with S0 (P < 0.05) and no statistically significant change between S1 and S2 (P = 0.87). pt = patient.
Tables
- TABLE 1.
Intersubject Averages of SUVorgan Measurements from [18F]FDHT PET/CT Images in 11 Women with Breast Cancer at S0, S1, and S2
Organ S0 S1 S2 Mean SD Mean SD Mean SD Aorta blood pool 4.8 0.7 4.4 0.4 4.6 0.5 Lumbar vertebral body 1.7 0.9 1.7 0.4 1.8 0.3 Cerebellum 0.29 0.07 0.32 0.05 0.30 0.05 Left ventricle blood pool 4.9 0.6 4.5 0.3 4.7 0.5 Kidneys 3.7 0.6 3.6 0.4 3.6 0.4 Liver 3.8 0.5 2.9 0.4 2.9 0.6 Lungs 0.85 0.22 0.82 0.21 0.77 0.18 Spleen 2.3 0.3 2.2 0.2 2.3 0.3 Whole body 0.80 0.06 0.77 0.07 0.79 0.05 - TABLE 2.
[18F]FDHT Radiation Dosimetry in Women with Breast Cancer at S0: Absorbed Dose in Target Organ at S0
Target organ Absorbed dose (mGy/MBq) Mean SD SD (%) Adrenals 2.3E−02 1.3E−03 5% Bone (endosteal cells) 1.4E−02 1.6E−03 11% Bone marrow (red, active) 2.1E−02 3.9E−03 19% Brain 5.3E−03 6.8E−04 13% Breast tissue 1.2E−02 3.0E−04 3% Colon 1.7E−02 6.5E−04 4% Extrathoracic region 8.0E−03 3.0E−04 4% Gallbladder wall 2.5E−02 1.7E−03 7% Heart wall 2.1E−02 1.2E−03 6% Kidneys 3.4E−02 3.8E−03 11% Liver 3.7E−02 3.9E−03 11% Lung 1.5E−02 1.8E−03 12% Lymphatic nodes 1.6E−02 7.0E−05 0% Muscle 1.3E−02 1.8E−04 1% Ovaries 2.6E−02 2.0E−03 7% Pancreas 1.9E−02 6.9E−04 4% Skin 9.1E−03 1.7E−04 2% Small intestine 1.9E−02 7.0E−04 4% Spleen 2.4E−02 2.2E−03 9% Stomach 1.6E−02 6.4E−04 4% Thymus 1.4E−02 5.9E−04 4% Thyroid 1.2E−02 4.0E−04 3% Urinary bladder wall 7.4E−02 1.1E−02 15% Uterus 3.8E−02 4.0E−03 11% Total body 1.3E−02 1.5E−04 1% Effective dose (mSv/MBq) 2.0E−02 5.0E−04 2%
Supplemental Data
Files in this Data Supplement:
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.